EPISODE · Dec 5, 2023 · 19 MIN
TALAPRO-2 (Talazoparib + Enzalutamide) in Prostate Cancer: Stephen Freedland and Neeraj Agarwal
from Oncology Data Advisor · host i3 Health
In this interview, Oncology Data Advisor Editorial Board member Dr. Stephen Freedland, Professor of Urology at Cedars-Sinai Medical Center, speaks with Dr. Neeraj Agarwal, Director of the Genitourinary (GU) Medical Oncology Group at Huntsman Cancer Institute, about his recent publication of the TALAPRO-2 study. Dr. Agarwal delves into the results of the trial, which investigated the efficacy of talazoparib plus enzalutamide for first-line metastatic castration-resistant prostate cancer (mCRPC), and their practice-changing significance.
What this episode covers
In this interview, Oncology Data Advisor Editorial Board member Dr. Stephen Freedland, Professor of Urology at Cedars-Sinai Medical Center, speaks with Dr. Neeraj Agarwal, Director of the Genitourinary (GU) Medical Oncology Group at Huntsman Cancer Institute, about his recent publication of the TALAPRO-2 study. Dr. Agarwal delves into the results of the trial, which investigated the efficacy of talazoparib plus enzalutamide for first-line metastatic castration-resistant prostate cancer (mCRPC), and their practice-changing significance.
NOW PLAYING
TALAPRO-2 (Talazoparib + Enzalutamide) in Prostate Cancer: Stephen Freedland and Neeraj Agarwal
No transcript for this episode yet
Similar Episodes
Jun 20, 2026 ·2m
Jun 15, 2026 ·3m
Jun 14, 2026 ·2m
Jun 13, 2026 ·3m
Jun 12, 2026 ·3m
Jun 11, 2026 ·3m